

What is claimed is:

1. An agent for use in screening of a medicament for treatment, prevention and/or diagnosis of an apoptosis-associated disease which comprises an apoptosis related protein which binds to NADE (p75^{NTR}-associated cell death executor) or a DNA encoding said protein.

2. The agent according to claim 1, wherein the apoptosis related protein binding to NADE is a protein selected from the group consisting of 14-3-3 protein, NIK/HGK protein, P33 ING relative protein, eIF4G protein and Huntingtin-binding protein 1.

3. A method for screening a medicament for treatment, prevention and/or diagnosis of an apoptosis-associated disease which comprises the step of detecting interaction between NADE and an apoptosis related protein which binds to NADE in the presence of a medicament to be tested.

4. The method according to claim 3, wherein the medicament tested is selected as a candidate of an effective medicament when the medicament has an effect on the interaction between NADE and an apoptosis related protein which binds to NADE.

5. The method according to claim 3, which comprises the steps of:
(a) subjecting NADE and the apoptosis related protein which binds to NADE to interaction with each other in the presence of the medicament to be tested,
(b) subjecting NADE and the apoptosis related protein which binds to NADE to interaction with each other in the absence of the medicament to be tested;
(c) detecting the interactions in the steps (a) and (b), and
(d) comparing the interactions in the steps (a) and (b) to chose the medicament having an effect on the interaction as a candidate of an effective medicament.

6. A medicament for treatment, prevention and/or diagnosis of an apoptosis-associated disease which is chosen by the method of claim 3.